The MAPK (ERK) Pathway - PMC Back to Top Skip to main content NIH NLM Logo Access keys
NCBI Homepage MyNCBI Homepage Main Content Main Navigation Preview improvements …

Purpose BRAF mutations promote melanoma cell proliferation and survival primarily through
activation of MEK. The purpose of this study was to determine the response rate (RR) for the …

New drugs targeting the mitogen-activated protein kinase (MAPK) pathway have generated
striking clinical response in melanoma therapy. From the discovery of BRAF mutation in …

Activating mutations in BRAFV600 are present in 40%-50% of patients with melanoma, and
mutantspecific inhibition with small molecule inhibitors of BRAF and MEK are associated …

The mitogen-activated protein kinase (MAPK) pathway is critical to oncogenic signaling in
the majority of patients with malignant melanoma. Driver mutations in both NRAS and BRAF …

In BRAF V600E melanoma patients, RAF inhibitor treatment causes a MEK-inhibitor-
sensitive, RAF-inhibitor-resistant adaptive reactivation of ERK signaling. In clinical trials …

Patients with advanced melanoma have traditionally had very poor prognosis. However,
since 2011 better understanding of the biology and epidemiology of this disease has …

The field of melanoma oncology has recently awakened with groundbreaking scientific
advances and innovative therapeutic strategies. New groups of small-molecule kinase …

Introduction: Selective inhibition of the MAPK pathway with BRAF and MEK inhibitors has
emerged as a key component of the treatment of BRAF-mutant unresectable/locally …

Melanoma is one of the most aggressive cancers in the world and is responsible for the
majority of skin cancer deaths. Recent advances in the field of immunotherapy using active …